Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers
用户3JCefs_FRcIo
1个月前
39
10
已关闭
DOI:
文献链接:
其他信息:
M Hulse, M Elkins, J Burtell, K Vykuntam…
Cancer …, 2023
aacrjournals.org
Abstract SMARCA2 (BRM) and SMARCA4 (BRG1) are mutually exclusive core catalytic subunits of the SWI/SNF complexes and use their ATPase domain to regulate the composition of nucleosomes. Between 4-5% of Non-Small Cell Lung Cancer (NSCLC) patients harbor SMARCA4 damaging mutations or SMARCA4 homo-deletions, resulting in loss of SMARCA4 protein expression. These SMARCA4-deleted cancer cells are predicted to be highly dependent on the paralog gene SMARCA2 for their survival. Therefore …
